Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries
Tóm tắt
The use of structural alerts to de-prioritize compounds with undesirable features as drug candidates has been gaining in popularity. Hundreds of molecular structural moieties have been proposed as structural alerts. An emerging issue is that strict application of these alerts will result in a significant reduction of the chemistry space for new drug discovery, as more than half of the oral drugs on the market match at least one of the alerts. To mitigate this issue, we propose to apply a rigorous statistical analysis to derive/validate structural alerts before use. To derive human liver toxicity structural alerts, we retrieved all small-molecule entries from LiverTox, a U.S. National Institutes of Health online resource for information on human liver injuries induced by prescription and over-the-counter drugs and dietary supplements. We classified the compounds into hepatotoxic, nonhepatotoxic, and possible hepatotoxic classes, and performed detailed statistical analyses to identify molecular structural fragments highly enriched in the hepatotoxic class beyond random distribution as structural alerts for human liver injuries. We identified 12 molecular fragments present in multiple marketed drugs that one can consider as common “drug-like” fragments, yet they are strongly associated with drug-induced human liver injuries. Thus, these fragments may be considered as robust hepatotoxicity structural alerts suitable for use in drug discovery screening programs. The use of structural alerts has contributed to the identification of many compounds with potential toxicity issues in modern drug discovery. However, with a large number of structural alerts published to date without proper validation, application of these alerts may restrict the chemistry space and prevent discovery of valuable drugs. To mitigate this issue, we showed how to use statistical analyses to develop a small, robust, and broadly applicable set of structural alerts.
Tài liệu tham khảo
Ahuja V, Sharma S. Drug safety testing paradigm, current progress and future challenges: an overview. J Appl Toxicol. 2014;34:576–94.
Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277:307–11.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.
Kalgutkar AS. Role of bioactivation in idiosyncratic drug toxicity: structure-toxicity relationships. In: Elfarra AA, editor. Advances in bioactivation research. Vol. 8. New York: Springer; 2008. p. 27–55.
Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–6.
Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci. 2002;4:E25.
Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474–85.
Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489–99.
Schuster D, Laggner C, Langer T. Why drugs fail – a study on side effects in new chemical entities. Curr Pharm Des. 2005;11:3545–59.
Nelson SD. Structure toxicity relationships – how useful are they in predicting toxicities of new drugs? Adv Exp Med Biol. 2001;500:33–43.
Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab. 2005;6:161–225.
Erve JC. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Expert Opin Drug Metab Toxicol. 2006;2:923–46.
Hewitt M, Enoch SJ, Madden JC, Przybylak KR, Cronin MT. Hepatotoxicity: a scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action. Crit Rev Toxicol. 2013;43:537–58.
Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol. 2011;24:1345–410.
Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol. 2005;35:325–61.
Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4:125ra131.
Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. Hepatology. 2013;57:873–4.
SMiles ARbitrary Target Specification (SMARTS) notation – a language for describing molecular patterns [http://www.daylight.com/dayhtml/doc/theory/theory.smarts.html]
Khalili H, Soudbakhsh A, Talasaz AH. Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine. Am J Health Syst Pharm. 2011;68:888–92.
Kalgutkar AS, Dalvie DK, O'Donnell JP, Taylor TJ, Sahakian DC. On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics. Curr Drug Metab. 2002;3:379–424.
Cruz TS, Faria PA, Santana DP, Ferreira JC, Oliveira V, Nascimento OR, et al. On the mechanisms of phenothiazine-induced mitochondrial permeability transition: thiol oxidation, strict Ca2+ dependence, and cyt c release. Biochem Pharmacol. 2010;80:1284–95.
Chan K, Truong D, Shangari N, O'Brien PJ. Drug-induced mitochondrial toxicity. Expert Opin Drug Metab Toxicol. 2005;1:655–69.
Nadanaciva S, Bernal A, Aggeler R, Capaldi R, Will Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro. 2007;21:902–11.
Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55–68.
Cover TM, Thomas JA. Elements of information theory. New York: John Wiley & Sons; 1991.